Multiplexed molecular profiling of lung cancer with malignant pleural effusion using next generation sequencing in Chinese patients
- Authors:
- Xingya Ruan
- Yonghua Sun
- Wei Wang
- Jianwei Ye
- Daoyun Zhang
- Ziying Gong
- Mingxia Yang
-
Affiliations: Department of Pulmonary and Critical Care Medicine, The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, Jiangsu 213000, P.R. China, Shanghai YunYing Medical Technology Co., Ltd., Shanghai 201600, P.R. China - Published online on: March 5, 2020 https://doi.org/10.3892/ol.2020.11446
- Pages: 3495-3505
-
Copyright: © Ruan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
 |
|
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Spiro SG and Silvestri GA: One hundred years of lung cancer. Am J Respir Crit Care Med. 172:523–529. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Cancer Genome Atlas Research Network, . Comprehensive molecular profiling of lung adenocarcinoma. Nature. 511:543–550. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Cancer Genome Atlas Research Network, . Comprehensive genomic characterization of squamous cell lung cancers. Nature. 489:519–525. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M, Sivachenko A, et al: Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 150:1107–1120. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Govindan R, Ding L, Griffith M, Subramanian J, Dees ND, Kanchi KL, Maher CA, Fulton R, Fulton L, Wallis J, et al: Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell. 150:1121–1134. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Campbell JD, Alexandrov A, Kim J, Wala J, Berger AH, Pedamallu CS, Shukla SA, Guo G, Brooks AN, Murray BA, et al: Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet. 48:607–616. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Weinstein IB and Joe A: Oncogene addiction. Cancer Res. 68:3077–3080; discussion 3080. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Inamura K: Lung Cancer: Understanding its molecular pathology and the 2015 WHO classification. Front Oncol. 7:1932017. View Article : Google Scholar : PubMed/NCBI | |
|
Kohno T, Nakaoku T, Tsuta K, Tsuchihara K, Matsumoto S, Yoh K and Goto K: Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. Transl Lung Cancer Res. 4:156–164. 2015.PubMed/NCBI | |
|
Tan L, Alexander M, Officer A, MacManus M, Mileshkin L, Jennens R, Herath D, de Boer R, Fox SB, Ball D and Solomon B: Survival difference according to mutation status in a prospective cohort study of Australian patients with metastatic non-small-cell lung carcinoma. Intern Med J. 48:37–44. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Han Y and Li J: Sample types applied for molecular diagnosis of therapeutic management of advanced non-small cell lung cancer in the precision medicine. Clin Chem Lab Med. 55:1817–1833. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Molina JR, Yang P, Cassivi SD, Schild SE and Adjei AA: Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Diaz LA Jr and Bardelli A: Liquid biopsies: Genotyping circulating tumor DNA. J Clin Oncol. 32:579–586. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Heitzer E, Ulz P and Geigl JB: Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem. 61:112–123. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Masters GA, Krilov L, Bailey HH, Brose MS, Burstein H, Diller LR, Dizon DS, Fine HA, Kalemkerian GP, Moasser M, et al: Clinical cancer advances 2015: Annual report on progress against cancer from the American society of clinical oncology. J Clin Oncol. 33:786–809. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Froudarakis ME: Pleural effusion in lung cancer: More questions than answers. Respiration. 83:367–376. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Roberts ME, Neville E, Berrisford RG, Antunes G and Ali NJ; BTS Pleural Disease Guideline Group, : Management of a malignant pleural effusion: British thoracic society pleural disease guideline 2010. Thorax. 65 (Suppl 2):ii32–ii40. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Chen YL, Lee CT, Lu CC, Yang SC, Chen WL, Lee YC, Yang CH, Peng SL, Su WC, Chow NH and Ho CL: Epidermal growth factor receptor mutation and anaplastic lymphoma kinase gene fusion: Detection in malignant pleural effusion by RNA or PNA analysis. PLoS One. 11:e01581252016. View Article : Google Scholar : PubMed/NCBI | |
|
Zarogoulidis K, Zarogoulidis P, Darwiche K, Tsakiridis K, Machairiotis N, Kougioumtzi I, Courcoutsakis N, Terzi E, Zaric B, Huang H, et al: Malignant pleural effusion and algorithm management. J Thorac Dis. 5 (Suppl 4):S413–S419. 2013.PubMed/NCBI | |
|
Akamatsu H, Koh Y, Kenmotsu H, Naito T, Serizawa M, Kimura M, Mori K, Imai H, Ono A, Shukuya T, et al: Multiplexed molecular profiling of lung cancer using pleural effusion. J Thorac Oncol. 9:1048–1052. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Agalioti T, Giannou AD and Stathopoulos GT: Pleural involvement in lung cancer. J Thorac Dis. 7:1021–1030. 2015.PubMed/NCBI | |
|
Tsai TH, Wu SG, Hsieh MS, Yu CJ, Yang JC and Shih JY: Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion. Lung Cancer. 88:208–214. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Tiran V, Stanzer S, Heitzer E, Meilinger M, Rossmann C, Lax S, Tsybrovskyy O, Dandachi N and Balic M: Genetic profiling of putative breast cancer stem cells from malignant pleural effusions. PLoS One. 12:e01752232017. View Article : Google Scholar : PubMed/NCBI | |
|
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Jian G, Songwen Z, Ling Z, Qinfang D, Jie Z, Liang T and Caicun Z: Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer. J Cancer Res Clin Oncol. 136:1341–1347. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Han HS, Eom DW, Kim JH, Kim KH, Shin HM, An JY, Lee KM, Choe KH, Lee KH, Kim ST, et al: EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: Discordance in pleural metastases. Clin Lung Cancer. 12:380–386. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Wu SG, Gow CH, Yu CJ, Chang YL, Yang CH, Hsu YC, Shih JY, Lee YC and Yang PC: Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma. Eur Respir J. 32:924–930. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang X, Zhao Y, Wang M, Yap WS and Chang AY: Detection and comparison of epidermal growth factor receptor mutations in cells and fluid of malignant pleural effusion in non-small cell lung cancer. Lung Cancer. 60:175–182. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Kimura H, Fujiwara Y, Sone T, Kunitoh H, Tamura T, Kasahara K and Nishio K: EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib. Br J Cancer. 95:1390–1395. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Wu SG, Yu CJ, Tsai MF, Liao WY, Yang CH, Jan IS, Yang PC and Shih JY: Survival of lung adenocarcinoma patients with malignant pleural effusion. Eur Respir J. 41:1409–1418. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Carter J, Miller JA, Feller-Kopman D, Ettinger D, Sidransky D and Maleki Z: Molecular profiling of malignant pleural effusion in metastatic non-small-cell lung carcinoma. The effect of preanalytical factors. Ann Am Thorac Soc. 14:1169–1176. 2017.PubMed/NCBI | |
|
Lin J, Gu Y, Du R, Deng M, Lu Y and Ding Y: Detection of EGFR mutation in supernatant, cell pellets of pleural effusion and tumor tissues from non-small cell lung cancer patients by high resolution melting analysis and sequencing. Int J Clin Exp Pathol. 7:8813–8822. 2014.PubMed/NCBI | |
|
Yang J, Lee OJ, Son SM, Woo CG, Jeong Y, Yang Y, Kwon J, Lee KH and Han HS: EGFR mutation status in lung adenocarcinoma-associated malignant pleural effusion and efficacy of EGFR tyrosine kinase inhibitors. Cancer Res Treat. 50:908–916. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Yeo CD, Kim JW, Kim KH, Ha JH, Rhee CK, Kim SJ, Kim YK, Park CK, Lee SH, Park MS and Yim HW: Detection and comparison of EGFR mutations in matched tumor tissues, cell blocks, pleural effusions, and sera from patients with NSCLC with malignant pleural effusion, by PNA clamping and direct sequencing. Lung Cancer. 81:207–212. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Han HS, Lim SN, An JY, Lee KM, Choe KH, Lee KH, Kim ST, Son SM, Choi SY, Lee HC and Lee OJ: Detection of EGFR mutation status in lung adenocarcinoma specimens with different proportions of tumor cells using two methods of differential sensitivity. J Thorac Oncol. 7:355–364. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Buttitta F, Felicioni L, Del Grammastro M, Filice G, Di Lorito A, Malatesta S, Viola P, Centi I, D'Antuono T, Zappacosta R, et al: Effective assessment of egfr mutation status in bronchoalveolar lavage and pleural fluids by next-generation sequencing. Clin Cancer Res. 19:691–698. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Biankin AV, Piantadosi S and Hollingsworth SJ: Patient-centric trials for therapeutic development in precision oncology. Nature. 526:361–370. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Celesti F, Celesti A, Wan J and Villari M: Why deep learning is changing the way to approach NGS data processing: A review. IEEE Rev Biomed Eng. 11:68–76. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Kamps R, Brandão RD, Bosch BJ, Paulussen AD, Xanthoulea S, Blok MJ and Romano A: Next-generation sequencing in oncology: Genetic diagnosis, risk prediction and cancer classification. Int J Mol Sci. 18:E3082017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu YC, Zhou YF, Wang WX, Xu CW, Zhuang W, Du KQ and Chen G: CEP72-ROS1: A novel ROS1 oncogenic fusion variant in lung adenocarcinoma identified by next-generation sequencing. Thorac Cancer. 9:652–655. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang X, Li Y, Liu C, Wang W, Li M, Lv D, Sun G, Chen H, Dong X, Miao Z, et al: Identification of a novel KIF13A-RET fusion in lung adenocarcinoma by next-generation sequencing. Lung Cancer. 118:27–29. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Liu L, Shao D, Deng Q, Tang H, Wang J, Liu J, Guo F, Lin Y, Peng Z, Mao M, et al: Next generation sequencing-based molecular profiling of lung adenocarcinoma using pleural effusion specimens. J Thorac Dis. 10:2631–2637. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
R Core Team, . A language and environment for statistical computing. R Foundation for Statistical Computing; Vienna, Austria: 2014, http://www.R-project.org/ | |
|
RStudio Team, . RStudio: Integrated Development for R. RStudio, Inc., Boston, MA, 2015. http://www.rstudio.com/ | |
|
Bai H, Xia J, Zhao X, Gong Z, Zhang D and Xiong L: Detection of EGFR mutations using target capture sequencing in plasma of patients with non-small-cell lung cancer. J Clin Pathol. 72:379–385. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Chmielecki J, Ross JS, Wang K, Frampton GM, Palmer GA, Ali SM, Palma N, Morosini D, Miller VA, Yelensky R, et al: Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin. Oncologist. 20:7–12. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, et al: EGF receptor gene mutations are common in lung cancers from ‘never smokers’ and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 101:13306–13311. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Hyman DM, Smyth LM, Donoghue MTA, Westin SN, Bedard PL, Dean EJ, Bando H, El-Khoueiry AB, Pérez-Fidalgo JA, Mita A, et al: AKT Inhibition in Solid Tumors With AKT1 Mutations. J Clin Oncol. 35:2251–2259. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Kim J, Yu L, Chen W, Xu Y, Wu M, Todorova D, Tang Q, Feng B, Jiang L, He J, et al: Wild-type p53 promotes cancer metabolic switch by inducing PUMA-dependent suppression of oxidative phosphorylation. Cancer Cell. 35:191–203.e8. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Ng KP, Hillmer AM, Chuah CT, Juan WC, Ko TK, Teo AS, Ariyaratne PN, Takahashi N, Sawada K, Fei Y, et al: A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med. 18:521–528. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
BRAF fusions in clinically advanced non-small cell lung cancer, . An emerging target for anti-BRAF therapies. J Clin Oncol. 35 (Suppl. 15):S90722017. View Article : Google Scholar | |
|
Caris Life Sciences, . BRAF mutations are potentially targetable alterations in a wide variety of solid cancers. https://www.carislifesciences.com/documents/braf-mutations-are-potentially-targetable-alterations-in-a-wide-variety-of-solid-cancers/December 2–2016 | |
|
Samuels Y and Waldman T: Oncogenic mutations of PIK3CA in human cancers. Curr Top Microbiol Immunol. 347:21–41. 2010.PubMed/NCBI | |
|
Ng PK, Li J, Jeong KJ, Shao S, Chen H, Tsang YH, Sengupta S, Wang Z, Bhavana VH, Tran R, et al: Systematic functional annotation of somatic mutations in cancer. Cancer Cell. 33:450–462.e10. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Wang LH, Wu CF, Rajasekaran N and Shin YK: Loss of tumor suppressor gene function in human cancer: An overview. Cell Physiol Biochem. 51:2647–2693. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W, Brace LE, Woods BA, Lin W, Zhang J, et al: Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov. 1:78–89. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Lui MMS, et al: Malignant pleural effusion from lung cancers with driver mutations. Curr Pulmonol Rep. 7:13–18. 2018. View Article : Google Scholar | |
|
Davies HE, Mishra EK, Kahan BC, Wrightson JM, Stanton AE, Guhan A, Davies CW, Grayez J, Harrison R, Prasad A, et al: Effect of an indwelling pleural catheter vs. chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: The TIME2 randomized controlled trial. JAMA. 307:2383–2389. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Sahn SA and Good JT Jr: Pleural fluid pH in malignant effusions. Diagnostic, prognostic, and therapeutic implications. Ann Intern Med. 108:345–349. 1988. View Article : Google Scholar : PubMed/NCBI | |
|
Heffner JE, Nietert PJ and Barbieri C: Pleural fluid pH as a predictor of survival for patients with malignant pleural effusions. Chest. 117:79–86. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Heffner JE, Heffner JN and Brown LK: Multilevel and continuous pleural fluid pH likelihood ratios for evaluating malignant pleural effusions. Chest. 123:1887–1894. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Stathopoulos GT, Sherrill TP, Karabela SP, Goleniewska K, Kalomenidis I, Roussos C, Fingleton B, Yull FE, Peebles RS Jr and Blackwell TS: Host-derived interleukin-5 promotes adenocarcinoma-induced malignant pleural effusion. Am J Respir Crit Care Med. 182:1273–1281. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Stathopoulos GT, Zhu Z, Everhart MB, Kalomenidis I, Lawson WE, Bilaceroglu S, Peterson TE, Mitchell D, Yull FE, Light RW and Blackwell TS: Nuclear factor-kappaB affects tumor progression in a mouse model of malignant pleural effusion. Am J Respir Cell Mol Biol. 34:142–150. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Stathopoulos GT, Psallidas I, Moustaki A, Moschos C, Kollintza A, Karabela S, Porfyridis I, Vassiliou S, Karatza M, Zhou Z, et al: A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion. J Natl Cancer Inst. 100:1464–1476. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Giannou AD, Marazioti A, Spella M, Kanellakis NI, Apostolopoulou H, Psallidas I, Prijovich ZM, Vreka M, Zazara DE, Lilis I, et al: Mast cells mediate malignant pleural effusion formation. J Clin Invest. 125:2317–2334. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Chen Y, Mathy NW and Lu H: The role of VEGF in the diagnosis and treatment of malignant pleural effusion in patients with nonsmall cell lung cancer (Review). Mol Med Rep. 17:8019–8030. 2018.PubMed/NCBI | |
|
Wu XZ, Zhou Q, Lin H, Zhai K, Wang XJ, Yang WB and Shi HZ: Immune regulation of toll-like receptor 2 engagement on CD4+ T cells in murine models of malignant pleural effusion. Am J Respir Cell Mol Biol. 56:342–352. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Stathopoulos GT and Kalomenidis I: Malignant pleural effusion: Tumor-host interactions unleashed. Am J Respir Crit Care Med. 186:487–492. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Psallidas I, Stathopoulos GT, Maniatis NA, Magkouta S, Moschos C, Karabela SP, Kollintza A, Simoes DC, Kardara M, Vassiliou S, et al: Secreted phosphoprotein-1 directly provokes vascular leakage to foster malignant pleural effusion. Oncogene. 32:528–535. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Cui R, Takahashi F, Ohashi R, Yoshioka M, Gu T, Tajima K, Unnoura T, Iwakami S, Hirama M, Ishiwata T, et al: Osteopontin is involved in the formation of malignant pleural effusion in lung cancer. Lung Cancer. 63:368–374. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Thomas R, Cheah HM, Creaney J, Turlach BA and Lee YC: Longitudinal measurement of pleural fluid biochemistry and cytokines in malignant pleural effusions. Chest. 149:1494–1500. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Ho CC, Liao WY, Wang CY, Lu YH, Huang HY, Chen HY, Chan WK, Chen HW and Yang PC: TREM-1 expression in tumor-associated macrophages and clinical outcome in lung cancer. Am J Respir Crit Care Med. 177:763–770. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Gopinathan G, Milagre C, Pearce OM, Reynolds LE, Hodivala-Dilke K, Leinster DA, Zhong H, Hollingsworth RE, Thompson R, Whiteford JR and Balkwill F: Interleukin-6 stimulates defective angiogenesis. Cancer Res. 75:3098–3107. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Yeh HH, Lai WW, Chen HH, Liu HS and Su WC: Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion. Oncogene. 25:4300–4309. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Q, Yu YX, Wang XJ and Wang Z and Wang Z: Diagnostic accuracy of interleukin-27 between tuberculous pleural effusion and malignant pleural effusion: A meta-analysis. Respiration. 95:469–477. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Ye ZJ, Zhou Q, Yin W, Yuan ML, Yang WB, Xiang F, Zhang JC, Xin JB, Xiong XZ and Shi HZ: Interleukin 22-producing CD4+ T cells in malignant pleural effusion. Cancer Lett. 326:23–32. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Sriram KB, Relan V, Clarke BE, Duhig EE, Yang IA, Bowman RV, Lee YC and Fong KM: Diagnostic molecular biomarkers for malignant pleural effusions. Future Oncol. 7:737–752. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Palaoro LA, Blanco AM, Gamboni M, Rocher AE and Rotenberg RG: Usefulness of ploidy, AgNOR and immunocytochemistry for differentiating benign and malignant cells in serous effusions. Cytopathology. 18:33–39. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Nam HS: Malignant pleural effusion: Medical approaches for diagnosis and management. Tuberc Respir Dis (Seoul). 76:211–217. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Light RW: Pleural effusions. Med Clin North Am. 95:1055–1070. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang B, Wu GP, Zhao YJ and Wang SC: Transcription expression and clinical significance of TTF-1 mRNA in pleural effusion of patients with lung cancer. Diagn Cytopathol. 36:849–854. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Woo CG, Son SM, Han HS, Lee KH, Choe KH, An JY, Man Lee K, Lim YH, Lee HC and Lee OJ: Diagnostic benefits of the combined use of liquid-based cytology, cell block, and carcinoembryonic antigen immunocytochemistry in malignant pleural effusion. J Thorac Dis. 10:4931–4939. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang F, Wang J, Zheng X, Hu L, Chen J, Jiang F and Wang Y: Clinical value of jointly detection pleural fluid Midkine, pleural fluid adenosine deaminase, and pleural fluid carbohydrate antigen 125 in the identification of nonsmall cell lung cancer-associated malignant pleural effusion. J Clin Lab Anal. 32:e225762018. View Article : Google Scholar : PubMed/NCBI | |
|
Han L, Jiang Q, Yao W, Fu T and Zeng Q: Thoracic injection of low-dose interleukin-2 as an adjuvant therapy improves the control of the malignant pleural effusions: A systematic review and meta-analysis base on Chinese patients. BMC Cancer. 18:7252018. View Article : Google Scholar : PubMed/NCBI | |
|
Xu L, Wang B, Gao M, Zhang Y, Qi Q, Li T, Li C, Wang A and Li Y: Intrapleural combination therapy with lobaplatin and erythromycin for non-small cell lung cancer-mediated malignant pleural effusion. Thorac Cancer. 9:950–955. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Tseng YH, Ho HL, Lai CR, Luo YH, Tseng YC, Whang-Peng J, Lin YH, Chou TY and Chen YM: PD-L1 expression of tumor cells, macrophages, and immune cells in non-small cell lung cancer patients with malignant pleural effusion. J Thorac Oncol. 13:447–453. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Li Y, Li X, Ma W and Dong Z: Conformational transition pathways of epidermal growth factor receptor kinase domain from multiple molecular dynamics simulations and bayesian clustering. J Chem Theory Comput. 10:3503–3511. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Pan AC, Weinreich TM, Shan Y, Scarpazza DP and Shaw DE: Assessing the accuracy of two enhanced sampling methods using EGFR kinase transition pathways: The influence of collective variable choice. J Chem Theory Comput. 10:2860–2865. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Sutto L and Gervasio FL: Effects of oncogenic mutations on the conformational free-energy landscape of EGFR kinase. Proc Natl Acad Sci USA. 110:10616–10621. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Ruan Z and Kannan N: Altered conformational landscape and dimerization dependency underpins the activation of EGFR by αC-β4 loop insertion mutations. Proc Natl Acad Sci USA. 115:E8162–E8171. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Sims D, Sudbery I, Ilott NE, Heger A and Ponting CP: Sequencing depth and coverage: Key considerations in genomic analyses. Nat Rev Genet. 15:121–132. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M and Riely GJ: Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 19:2240–2247. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Yang M, Topaloglu U, Petty WJ, Pagni M, Foley KL, Grant SC, Robinson M, Bitting RL, Thomas A, Alistar AT, et al: Circulating mutational portrait of cancer: Manifestation of aggressive clonal events in both early and late stages. J Hematol Oncol. 10:1002017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Z, Yang JJ, Huang J, Ye JY, Zhang XC, Tu HY, Han-Zhang H and Wu YL: Lung adenocarcinoma harboring EGFR T790M and in trans C797S responds to combination therapy of first- and third-generation EGFR TKIs and shifts allelic configuration at resistance. J Thorac Oncol. 12:1723–1727. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Lin YT, Liu YN, Wu SG, Yang JC and Shih JY: Epidermal growth factor receptor tyrosine kinase inhibitor-sensitive exon 19 insertion and exon 20 insertion in patients with advanced non-small-cell lung cancer. Clin Lung Cancer. 18:324–332.e1. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ibrahim U, Saqib A and Atallah JP: EGFR exon 18 delE709_T710insD mutated stage IV lung adenocarcinoma with response to afatinib. Lung Cancer. 108:45–47. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, et al: Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 361:958–967. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Chic N, Mayo-de-Las-Casas C and Reguart N: Successful treatment with gefitinib in advanced non-small cell lung cancer after acquired resistance to osimertinib. J Thorac Oncol. 12:e78–e80. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ganesan P, Ali SM, Wang K, Blumenschein GR, Esmaeli B, Wolff RA, Miller VA, Stephens PJ, Ross JS, Palmer GA and Janku F: Epidermal growth factor receptor P753S mutation in cutaneous squamous cell carcinoma responsive to cetuximab-based therapy. J Clin Oncol. 34:e34–37. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Costa DB: Kinase inhibitor-responsive genotypes in EGFR mutated lung adenocarcinomas: Moving past common point mutations or indels into uncommon kinase domain duplications and rearrangements. Transl Lung Cancer Res. 5:331–337. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, Lai Z, Markovets A, Vivancos A, Kuang Y, et al: Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 21:560–562. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zou J, Bella AE, Chen Z, Han X, Su C, Lei Y and Luo H: Frequency of EGFR mutations in lung adenocarcinoma with malignant pleural effusion: Implication of cancer biological behaviour regulated by EGFR mutation. J Int Med Res. 42:1110–1117. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Tsai MF, Chang TH, Wu SG, Yang HY, Hsu YC, Yang PC and Shih JY: EGFR-L858R mutant enhances lung adenocarcinoma cell invasive ability and promotes malignant pleural effusion formation through activation of the CXCL12-CXCR4 pathway. Sci Rep. 5:135742015. View Article : Google Scholar : PubMed/NCBI | |
|
Lee JG and Wu R: Erlotinib-cisplatin combination inhibits growth and angiogenesis through c-MYC and HIF-1α in EGFR-mutated lung cancer in vitro and in vivo. Neoplasia. 17:190–200. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Mertens F and Tayebwa J: Evolving techniques for gene fusion detection in soft tissue tumours. Histopathology. 64:151–162. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Martinengo C, Poggio T, Menotti M, Scalzo MS, Mastini C, Ambrogio C, Pellegrino E, Riera L, Piva R, Ribatti D, et al: ALK-dependent control of hypoxia-inducible factors mediates tumor growth and metastasis. Cancer Res. 74:6094–6106. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Z, Wu X, Han X, Cheng G, Mu X, Zhang Y, Cui D, Liu C, Liu D and Shi Y: ALK gene expression status in pleural effusion predicts tumor responsiveness to crizotinib in Chinese patients with lung adenocarcinoma. Chin J Cancer Res. 28:606–616. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Liu L, Zhan P, Zhou X, Song Y, Zhou X, Yu L and Wang J: Detection of EML4-ALK in lung adenocarcinoma using pleural effusion with FISH, IHC, and RT-PCR methods. PLoS One. 10:e01170322015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhong J, Li X, Bai H, Zhao J, Wang Z, Duan J, An T, Wu M, Wang Y, Wang S and Wang J: Malignant pleural effusion cell blocks are substitutes for tissue in EML4-ALK rearrangement detection in patients with advanced non-small-cell lung cancer. Cytopathology. 27:433–443. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Raparia K, Villa C, Raj R and Cagle PT: Peripheral lung adenocarcinomas with KRAS mutations are more likely to invade visceral pleura. Arch Pathol Lab Med. 139:189–193. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Renaud S, Seitlinger J, Falcoz PE, Schaeffer M, Voegeli AC, Legrain M, Beau-Faller M and Massard G: Specific KRAS amino acid substitutions and EGFR mutations predict site-specific recurrence and metastasis following non-small-cell lung cancer surgery. Br J Cancer. 115:346–353. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Agalioti T, Giannou AD, Krontira AC, Kanellakis NI, Kati D, Vreka M, Pepe M, Spella M, Lilis I, Zazara DE, et al: Mutant KRAS promotes malignant pleural effusion formation. Nat Commun. 8:152052017. View Article : Google Scholar : PubMed/NCBI | |
|
Wu SG, Liu YN, Yu CJ, Yang PC and Shih JY: Association of BIM deletion polymorphism with intrinsic resistance to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma. JAMA Oncol. 2:826–828. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Lee JH, Lin YL, Hsu WH, Chen HY, Chang YC, Yu CJ, Shih JY, Lin CC, Chen KY, Ho CC, et al: Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer. J Thorac Oncol. 9:1385–1392. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Cardona AF, Rojas L, Wills B, Arrieta O, Carranza H, Vargas C, Otero J, Corrales-Rodriguez L, Martín C, Reguart N, et al: BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations. Oncotarget. 7:68933–68942. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Xia J, Bai H, Yan B, Li R, Shao M, Xiong L and Han B: Mimicking the BIM BH3 domain overcomes resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer. Oncotarget. 8:108522–108533. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao M, Zhang Y, Cai W, Li J, Zhou F, Cheng N, Ren R, Zhao C, Li X, Ren S, et al: The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer. Cancer. 120:2299–2307. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Lee JK, Shin JY, Kim S, Lee S, Park C, Kim JY, Koh Y, Keam B, Min HS, Kim TM, et al: Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: An exploratory study. Ann Oncol. 24:2080–2087. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Isobe K, Hata Y, Tochigi N, Kaburaki K, Kobayashi H, Makino T, Otsuka H, Sato F, Ishida F, Kikuchi N, et al: Clinical significance of BIM deletion polymorphism in non-small-cell lung cancer with epidermal growth factor receptor mutation. J Thorac Oncol. 9:483–487. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Wu SG, Chang YL, Yu CJ, Yang PC and Shih JY: Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors. ERJ Open Res. 3:00092–2016. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wu M, Pan X, Xu Y, Wu S, Wu X and Chen B: Methodological comparison of the allele refractory mutation system and direct sequencing for detecting EGFR mutations in NSCLC, and the association of EGFR mutations with patient characteristics. Oncol Lett. 16:1087–1094. 2018.PubMed/NCBI | |
|
Shi Y, Au JS, Thongprasert S, Srinivasan S, Tsai CM, Khoa MT, Heeroma K, Itoh Y, Cornelio G and Yang PC: A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 9:154–162. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Tseng CH, Chiang CJ, Tseng JS, Yang TY, Hsu KH, Chen KC, Wang CL, Chen CY, Yen SH, Tsai CM, et al: EGFR mutation, smoking, and gender in advanced lung adenocarcinoma. Oncotarget. 8:98384–98393. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Kota R, Gundeti S, Gullipalli M, Linga VG, Maddali LS and Digumarti R: Prevalence and outcome of epidermal growth factor receptor mutations in non-squamous non-small cell lung cancer patients. Lung India. 32:561–565. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Aunan JR, Cho WC and Soreide K: The biology of aging and cancer: A brief overview of shared and divergent molecular hallmarks. Aging Dis. 8:628–642. 2017. View Article : Google Scholar : PubMed/NCBI |
